Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | FPR1 | P21462 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.30 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25327618 | 0.94 | MGLL (0.38) | MGLLSCN9ASCN10AFPR1FPR2 | |
| SCHEMBL25328035 | 0.91 | MGLL (0.41) | MGLLSCN9ASCN10AHCRTR1KCNH2 | |
| SCHEMBL25325817 | 0.87 | MGLL (0.41) | MGLL | |
| SCHEMBL30553271 | 0.87 | MGLL (0.41) | MGLL | |
| SCHEMBL25323434 | 0.86 | MGLL (0.40) | MGLL | |
| SCHEMBL25324110 | 0.86 | MGLL (0.39) | MGLLSCN9ASCN10AHCRTR1 | |
| SCHEMBL25326753 | 0.85 | MGLL (0.38) | MGLLSCN9AHCRTR1DGAT1KCNH2 | |
| SCHEMBL25326128 | 0.84 | MGLL (0.38) | MGLL | |
| SCHEMBL30553209 | 0.84 | MGLL (0.38) | MGLL | |
| SCHEMBL25324842 | 0.84 | MGLL (0.39) | MGLLSCN9AHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | MGLL 3523/4885SCN9A 1164/4885SCN10A 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.